Their results indicated that FGFR3 mutations were more frequently observed in neoplasms with low malignant potential, at 77%, and in tumors TaG1, at 61%, and TaG2, at 58%, than in tumors TaG3, at 34%, and T1G3, at 17%. The gene discussed is FGFR3; the disease is neoplasm.